Search clinical trials for: paquinimod (ABR-215757)

Total 3236 results

Active Biotech AB

Completed

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Denmark, Sweden
Active Biotech AB

Completed

A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Healthy

Sweden
Active Biotech AB

Completed

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Prostate Cancer

United States, Canada, Sweden
Active Biotech AB

Completed

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer

France, Poland, Ukraine, United Kingdom, United States, China, Germany, Taiwan, Spain, Belgium, Colombia, Israel, Bulgaria, India, Panama, Romania, Netherlands, Greece, Sweden, Korea, Republic of, Australia, Canada, Chile, New Zealand, ... and more
Ipsen

Terminated

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (TasQ003)

Prostatic Neoplasms, Castration-Resistant

China, Korea, Republic of, Taiwan
Ipsen

Completed

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Metastatic Renal Cell Cancer | Advanced or Metastatic Hepatocellular Cancer | Advanced or Metastatic Ovarian Cancer | Advanced or Metastatic Gastric Carcinoma

Belgium, Canada, France, Spain, United Kingdom
Active Biotech AB

Active, not recruiting

A Study of Laquinimod Eye-drops in Healthy Participants

Eye Diseases

Austria
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Active Biotech AB

Completed

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)

Systemic Sclerosis

Germany, Sweden, Switzerland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod (LEGATO-HD)

Huntington's Disease

United States, Canada, Czechia, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Laquinimod Phase IIa Study in Active Crohn's Disease

Crohn's Disease

Belgium, France, Israel, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Lupus Arthritis

United States, Canada
Teva Pharmaceutical Industries, Ltd.

Terminated

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Relapsing Remitting Multiple Sclerosis

Czechia, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
IRCCS Eugenio Medea

Recruiting

Pragmatic Abilities in Children With Acquired Brain Injury (ABIabc)

Acquired Brain Injury | Pragmatic Communication Disorder

Italy
Nimbic Systems, LLC
Baylor College of Medicine; National Institute of General Medical Sciences...

Completed

Air Barrier System for the Prevention of Surgical Site Infection (ABS)

Surgical Site Infection

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

Pharmacokinetics | Pharmacodynamics

Germany
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Merck Sharp & Dohme LLC

Completed

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Schizophrenia
Facet Biotech

Completed

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Graft vs Host Disease

United States
Aligos Therapeutics

Terminated

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Chronic Hepatitis B

New Zealand, Bulgaria, Moldova, Republic of, Romania
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
Ankara City Hospital Bilkent

Not yet recruiting

Maternal Diabetes in Newborns With Hearing Loss (GDM)

Hearing Loss | Gestational Diabetes | Pregestational Diabetes

Turkey
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Metastatic Colorectal Cancer
Quan Dong Nguyen
Global Ophthalmic Research Center (GORC)

Recruiting

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (LION)

Inflammation | Uveitis

United States
Intermountain Health Care, Inc.

Completed

Test of Chamber Pressure to Divers and Chamber Attendants (TOP-DIVER)

Traumatic Brain Injury

United States
M.D. Anderson Cancer Center

Withdrawn

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
F2G Biotech GmbH
PRA Health Sciences

Completed

Absorption, Metabolism and Excretion of 14C-olorofim in Man (hAME)

Invasive Fungal Infections

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Tel-Aviv Sourasky Medical Center

Unknown

Arthroscopic Rotator Interval Closure in Shoulder Instability Repair

Recurrent Shoulder Dislocations

Israel
Centre Cardiologique du Nord
Universita degli Studi di Genova; Henri Mondor University Hospital; Pitié-Salpêtrière...

Enrolling by invitation

Outcomes of Type A Aortic Dissection Repair (STAAD)

Aortic Valve Insufficiency | Aortic Diseases | Ascending Aortic Dissection | Aortic Arch | Aortic Root Dissection | Aortic Root Dilatation | Type A Aortic Dissection

France
Tanta University

Completed

MRA and ABR as Early Predictors of Bilirubin-Induced Neurologic Dysfunction in Full-term Jaundiced Neonates

Neonatal Hyperbilirubinemia

Egypt
Indiana University

Completed

Comparing Brief Relaxation Period to Virtual Reality Period in Reducing Dental Anxiety Prior to Root Canal Treatment

Dental Anxiety

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Hematologic Malignancies

United States, Australia
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

SLE

China
Dart NeuroScience, LLC

Completed

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

Healthy Volunteers (Part 1) | Major Depressive Disorder (Part 2)

United States
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Active Biotech AB

Completed

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Renal Cell Carcinoma | Pancreatic Cancer | Non-Small-Cell Lung Carcinoma

United States, Norway, United Kingdom
Ascentage Pharma Group Inc.

Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

T-Prolymphocytic Leukemia

United States
Sir Ganga Ram Hospital

Completed

Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants

Latent Iron Deficiency at Birth

Search clinical trials for: paquinimod (ABR-215757)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations